Hyaluronic acid fuels pancreatic cancer cell growth
- University of Michigan, United States
- The University of Texas MD Anderson Cancer Center, United States
- Memorial Sloan Kettering Cancer Center, United States
- University of Southern California, United States
Abstract
Rewired metabolism is a hallmark of pancreatic ductal adenocarcinomas (PDA). Previously, we demonstrated that PDA cells enhance glycosylation precursor biogenesis through the hexosamine biosynthetic pathway (HBP) via activation of the rate limiting enzyme, glutamine-fructose 6-phosphate amidotransferase 1 (GFAT1). Here, we genetically ablated GFAT1 in human PDA cell lines, which completely blocked proliferation in vitro and led to cell death. In contrast, GFAT1 knockout did not preclude the growth of human tumor xenografts in mice, suggesting that cancer cells can maintain fidelity of glycosylation precursor pools by scavenging nutrients from the tumor microenvironment. We found that hyaluronic acid (HA), an abundant carbohydrate polymer in pancreatic tumors composed of repeating N-acetyl-glucosamine (GlcNAc) and glucuronic acid sugars, can bypass GFAT1 to refuel the HBP via the GlcNAc salvage pathway. Together, these data show HA can serve as a nutrient fueling PDA metabolism beyond its previously appreciated structural and signaling roles.
Data availability
All data generated or analysed during this study are included in the manuscript and supporting file; raw images have been provided for all western blots in the Source Data file.
Article and author information
Author details
Funding
National Cancer Institute (Cancer Biology Training Grant,T32AI007413)
- Peter K Kim
- Samuel A Kerk
Thompson Family Foundation (Research Grant)
- Kayvan R Keshari
STARR Cancer Consortium (Research Grant)
- Kayvan R Keshari
National Cancer Institute (Cancer Center Support Grant,P30CA008748)
- Kayvan R Keshari
American Association for Cancer Research (Pathway to Leadership award,13-70-25-LYSS)
- Costas Lyssiotis
V Foundation for Cancer Research (Junior Scholar Award,V2016-009)
- Costas Lyssiotis
Sidney Kimmel Foundation (Kimmel Scholar Award,SKF-16-005)
- Costas Lyssiotis
American Association for Cancer Research (NextGen Grant for Transformative Cancer Research,17-20-01-LYSS)
- Costas Lyssiotis
National Cancer Institute (Cancer Center Support Grant,P30 CA046592)
- Costas Lyssiotis
National Cancer Institute (R37CA237421)
- Costas Lyssiotis
National Cancer Institute (R01CA248160)
- Costas Lyssiotis
National Cancer Institute (Predoctoral Fellowship,F31CA243344)
- Peter K Kim
National Cancer Institute (R01CA244931)
- Costas Lyssiotis
National Institutes of Health (U24DK097153)
- Costas Lyssiotis
Charles Woodson Research Fund (Research Support)
- Costas Lyssiotis
UM Pediatric Brain Tumor Initiative (Research Support)
- Costas Lyssiotis
National Cancer Institute (F99/K00CA264414)
- Samuel A Kerk
National Institute of Child Health and Human Development (T32HD007505)
- Megan Radyk
National Cancer Institute (Pathway to Independence Award,K99CA241357)
- Christopher J Halbrook
National Institute of Diabetes and Digestive and Kidney Diseases (Postdoctoral Support,P30DK034933)
- Christopher J Halbrook
National Cancer Institute (F31CA24745701)
- Samuel A Kerk
National Cancer Institute (R01CA237466)
- Kayvan R Keshari
National Cancer Institute (R01CA252037)
- Kayvan R Keshari
National Cancer Institute (R21CA212958)
- Kayvan R Keshari
Stand Up To Cancer (Research Grant)
- Kayvan R Keshari
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Reviewing Editor
- Lydia W S Finley, Memorial Sloan Kettering Cancer Center, United States
Ethics
Animal experimentation: Animal experiments were conducted in accordance with the Office of Laboratory Animal Welfare and approved by the Institutional Animal Care and Use Committees of the University of Michigan. Protocol#: PRO00008877
Version history
- Received: September 1, 2020
- Accepted: December 21, 2021
- Accepted Manuscript published: December 24, 2021 (version 1)
- Accepted Manuscript updated: December 29, 2021 (version 2)
- Version of Record published: January 5, 2022 (version 3)
Copyright
© 2021, Kim et al.
This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 8,654
- views
-
- 867
- downloads
-
- 44
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Hyaluronic acid fuels pancreatic cancer cell growth
eLife 10:e62645.
https://doi.org/10.7554/eLife.62645
Further reading
-
- Cancer Biology
Tyrosine kinase inhibitors (TKI) directed against MET have been recently approved to treat advanced non-small cell lung cancer (NSCLC) harbouring activating MET mutations. This success is the consequence of a long characterization of MET mutations in cancers, which we propose to outline in this review. MET, a receptor tyrosine kinase (RTK), displays in a broad panel of cancers many deregulations liable to promote tumour progression. The first MET mutation was discovered in 1997, in hereditary papillary renal cancer (HPRC), providing the first direct link between MET mutations and cancer development. As in other RTKs, these mutations are located in the kinase domain, leading in most cases to ligand-independent MET activation. In 2014, novel MET mutations were identified in several advanced cancers, including lung cancers. These mutations alter splice sites of exon 14, causing in-frame exon 14 skipping and deletion of a regulatory domain. Because these mutations are not located in the kinase domain, they are original and their mode of action has yet to be fully elucidated. Less than five years after the discovery of such mutations, the efficacy of a MET TKI was evidenced in NSCLC patients displaying MET exon 14 skipping. Yet its use led to a resistance mechanism involving acquisition of novel and already characterized MET mutations. Furthermore, novel somatic MET mutations are constantly being discovered. The challenge is no longer to identify them but to characterize them in order to predict their transforming activity and their sensitivity or resistance to MET TKIs, in order to adapt treatment.
-
- Cancer Biology
- Genetics and Genomics
Relapse of acute myeloid leukemia (AML) is highly aggressive and often treatment refractory. We analyzed previously published AML relapse cohorts and found that 40% of relapses occur without changes in driver mutations, suggesting that non-genetic mechanisms drive relapse in a large proportion of cases. We therefore characterized epigenetic patterns of AML relapse using 26 matched diagnosis-relapse samples with ATAC-seq. This analysis identified a relapse-specific chromatin accessibility signature for mutationally stable AML, suggesting that AML undergoes epigenetic evolution at relapse independent of mutational changes. Analysis of leukemia stem cell (LSC) chromatin changes at relapse indicated that this leukemic compartment underwent significantly less epigenetic evolution than non-LSCs, while epigenetic changes in non-LSCs reflected overall evolution of the bulk leukemia. Finally, we used single-cell ATAC-seq paired with mitochondrial sequencing (mtscATAC) to map clones from diagnosis into relapse along with their epigenetic features. We found that distinct mitochondrially-defined clones exhibit more similar chromatin accessibility at relapse relative to diagnosis, demonstrating convergent epigenetic evolution in relapsed AML. These results demonstrate that epigenetic evolution is a feature of relapsed AML and that convergent epigenetic evolution can occur following treatment with induction chemotherapy.
